Leiden: BioFocus to market ZoBio NMR technology

Marketing agreement

ZoBio, a spin-out from the University of Leiden, has signed an agreement with BioFocus to market and sell its proprietary fragment-based NMR (nuclear magnetic resonance) technologies as stand-alone or combined products.

ZoBio’s proprietary fragment–based screening technology Target Immobilized NMR Screening (TINS) detects weak intermolecular interactions between ligands and targets with high sensitivity. This technology can be applied to optimise and accelerate drug research by screening drug fragment libraries using a minimal amount of target protein in the microgram range. 

The agreement will expand BioFocus’ drug candidate portfolio, as stated by BioFocus Vice President Chris Newton: “The addition of the ZoBio technology to BioFocus DPI’s offerings will enhance our hit finding capabilities. The technology will expand our fragment-based screening obtained through the acquisition of Sareum’s X-ray crystallography.”

Gregg Siegal, of ZoBio, said: “We are pleased that BioFocus has selected ZoBio as a strategic partner for their fragment-based drug discovery services. We feel the combination will offer customers proven, cutting-edge technologies to meet their biggest drug discovery challenges.”